L-5-HTP

Also sold as: 5-HTP

Best-in-class: 5-Hydroxytryptophan

Direct serotonin precursor derived from Griffonia seed — one step closer to serotonin than tryptophan.

How L-5-HTP actually works

5-hydroxytryptophan sits one enzymatic step from serotonin, downstream of the rate-limiting tryptophan hydroxylase — which is precisely why it works and why it needs care. Bypassing the regulated step means conversion is no longer controlled, and because aromatic amino acid decarboxylase is present throughout the body, much of the conversion happens peripherally rather than in the brain.

Where to get L-5-HTP

The evidence for L-5-HTP

Graded by what exists behind each claim.

✅ Clinically validated

• Small RCTs suggest benefit for mood and appetite regulation; evidence is promising but smaller than for pharmaceuticals.
• Studied for reducing sleep latency and appetite/craving.

📊 Correlative data

• Low serotonergic tone is associated with low mood, carbohydrate craving and poor sleep.

🧪 Theoretical / extrapolated benefits

• Proposed to raise central serotonin; the concern is unproven long-term effects and the theoretical need to pair with cofactors.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What L-5-HTP actually does

Serotonin is made in two steps. Tryptophan hydroxylase — TPH1 in the gut and periphery, TPH2 in serotonergic neurons — adds a hydroxyl to the 5-position of tryptophan using tetrahydrobiopterin and iron, and that step is rate-limiting and feedback-regulated. Then aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase), a pyridoxal-5'-phosphate enzyme, strips the carboxyl group off 5-hydroxytryptophan to give serotonin.

Swallowing 5-HTP skips the regulated step, and that is the entire rationale for the product. Give tryptophan and the body decides how much serotonin to make, because the hydroxylase is controlled. Give 5-HTP and the decision has already been taken: the only enzyme left is a decarboxylase that is fast, abundant and not feedback-regulated. That is a real pharmacological argument and it is the reason 5-HTP is not just a more expensive tryptophan.

It is also, exactly, the reason the product is difficult, because that decarboxylase is everywhere except where you want it. AADC is expressed at high levels in the gut wall, liver, kidney and vascular endothelium. An oral dose of 5-HTP meets all of those before it meets the brain, and serotonin itself does not cross the blood–brain barrier. So every molecule decarboxylated in the periphery is a molecule that can never contribute to central serotonin — and it becomes peripheral serotonin instead, which is the direct cause of the nausea that limits the dose. The clinical workaround has always been to co-administer a peripheral decarboxylase inhibitor — carbidopa or benserazide — which cannot cross into the brain and therefore blocks the loss reaction without blocking the useful one.

Which sets up the most interesting thing about the bottle this card links to. The filed label carries, per two-capsule serving, 5-HTP 100 mg and vitamin B6 6.8 mg as pyridoxal 5'-phosphate Office of Dietary Supplements 2023. P5P is the coenzyme of AADC. Adding it is the standard ‘you need the cofactor’ argument, and the pharmacology says it is at best ambiguous and at worst backwards: if AADC really were cofactor-limited, supplying P5P systemically would accelerate the abundant peripheral enzyme at least as much as the central one — the opposite of what carbidopa is given to achieve. In a B6-replete person AADC is not cofactor-limited at all and the addition does nothing. This is reasoning from enzyme distribution rather than from a trial; no study has compared 5-HTP with and without added B6 in a human, and that is the missing experiment.

One more piece of chemistry that decides the dosing schedule. 5-HTP is short-lived, and the case for reformulating it as a slow-release product rests explicitly on overcoming the poor pharmacokinetics of the immediate-release compound Jacobsen 2016. A short half-life plus a fast unregulated decarboxylase means an immediate-release capsule produces a spike and then a trough — peak peripheral serotonin, which is the nausea, followed by nothing.

Cell, rodent, human — and where it stops

Human pharmacokinetics first, because for once they exist and they are good. In five patients at steady state, oral L-5-HTP had a systemic availability of 47 to 84%, mean 69.2% ± 4.7 SEM, reaching maximum plasma concentrations at 1.8 to 3.3 hours, with transitory nausea and vomiting in only a few instances Magnussen 1980. Roughly seventy percent bioavailability is far better than most things on this site — the molecule genuinely gets in.

The depression evidence, with the numbers that make it unusable. A systematic review located 108 trials of tryptophan and 5-HTP for depression and found that only two, with 64 patients between them, met basic quality criteria. In those two, the compounds beat placebo: Peto odds ratio 4.10 (95% CI 1.28 to 13.15), risk difference 0.36, number needed to treat 2.78. The conclusion was that the evidence suggests effectiveness but is of insufficient quality to recommend Shaw 2002. An NNT of 2.78 would be extraordinary if it came from 6,400 patients. It comes from 64, and 106 other trials were excluded.

The appetite evidence is smaller and cleaner and at a dose nobody takes. Obese adults were given 900 mg a day of 5-HTP over two consecutive six-week periods, with a 5,040 kJ/day diet prescribed for the second. There was significant weight loss in both periods, a reduction in carbohydrate intake, and the consistent presence of early satiety Cangiano 1992. Early satiety is a specific, mechanistically coherent finding: peripheral serotonin acting on the gut is exactly what would produce it.

Now the dose arithmetic, and this one runs in the opposite direction from most pages here. The appetite trial used 900 mg/day Cangiano 1992. The card says 50–100 mg, often at night. The filed label says one to two capsules three times daily, which is 150 to 300 mg a day Office of Dietary Supplements 2023. Three different numbers spanning an eighteen-fold range, on the same product, on the same page. The label's own directions are up to six times the card's dose, and the trial's dose is three times the label's maximum.

So the specific obstacle is not absorption and it is not receptor pharmacology. It is that the useful dose and the tolerable dose are set by different organs. The molecule is ~70% bioavailable Magnussen 1980, but AADC in gut and liver converts much of it to peripheral serotonin, which produces the nausea that caps the dose long before the brain sees a large exposure. That is why the serious clinical literature pairs 5-HTP with a peripheral decarboxylase inhibitor and why the modern proposal is a slow-release formulation aimed squarely at the pharmacokinetics Jacobsen 2016. An immediate-release capsule taken alone is the one version of this drug that the pharmacology says is hardest to make work.

The second obstacle is that the trial base is small enough to be fragile. Sixty-four patients across two acceptable trials for the mood claim Shaw 2002; one appetite study at a dose nobody sells Cangiano 1992. The sleep claim, which is what most people buy it for, has the thinnest file of the three.

L-5-HTP — which form, and does it matter

Retail 5-HTP is a plant extract, and that fact is the whole safety history. The material is extracted from the seed of the West African vine Griffonia simplicifolia, which accumulates free 5-HTP. It is not fermented like tryptophan and not synthesized. What matters is that a plant extract carries whatever else the extraction pulled through, and somebody looked.

The contaminant finding, stated exactly. All eight samples of commercially available 5-HTP analyzed by HPLC-MS contained three or more contaminants of the ‘peak X’ family Klarskov 1999. Peak X is the label for the case-associated impurity family found in the tryptophan products linked to the eosinophilia-myalgia syndrome epidemic. Eight of eight, three or more each.

And the counterweight, which belongs on the same page and is usually omitted by whichever side is arguing. A safety review written after two decades of worldwide use concluded that no definitive cases of toxicity have emerged and that extensive analyses of several sources of 5-HTP have shown no toxic contaminants Das 2004. Both statements are in the literature. Reconciling them honestly: peak X compounds are detectable in commercial material and have not been shown to cause disease at the levels found, and detection limits improved faster than the epidemiology did.

The formulation variable that actually has a rationale is release rate. The published case for slow-release 5-HTP is explicitly about overcoming the poor pharmacokinetics of the immediate-release compound Jacobsen 2016, and it follows directly from the enzymology: a slow input keeps plasma 5-HTP above the level where central conversion can occur without producing the peripheral spike that causes nausea. Almost every retail product is immediate-release. This is the one place where a formulation claim would be worth paying for and where the products are the wrong way round.

The added B6, weighed properly. The label carries 6.8 mg of P5P per 100 mg of 5-HTP Office of Dietary Supplements 2023. That is a modest amount of vitamin B6, so it is not a neuropathy concern at the labeled dose. The question is whether it helps, and the answer from enzyme distribution is that it can only accelerate a decarboxylation that is mostly happening in the wrong compartment. Nobody has tested it either way.

What to buy, then. A product that states its Griffonia source and its purity testing; slow-release if you can find one Jacobsen 2016; and a dose you have chosen deliberately, because the card and the label of the same product disagree by up to six-fold Office of Dietary Supplements 2023.

What would have to be true, and how you would know it was not

1. Nausea, which is the dose-finding instrument rather than a side effect. Predict it, predict it is dose-related, and predict it arrives within an hour or two of the first dose — peak plasma 5-HTP is at 1.8 to 3.3 hours Magnussen 1980 and the nausea is peripheral serotonin, not a central effect. Taking it with food and starting at 50 mg is not gentleness, it is the correct way to find the dose at which peripheral conversion is not overwhelming. If 50 mg causes nausea, the answer is not 100 mg.

2. Sleep onset latency, timed and counted. Log minutes to sleep for two weeks before the first capsule and two weeks on. Predict a change within one to two weeks or not at all: nothing accumulates here, the compound sits one enzymatic step from serotonin, and a fortnight at a tolerated dose is a complete test.

3. Early satiety and carbohydrate intake, which is the best-supported behavioral endpoint and the one nobody measures. Predict reduced carbohydrate intake and earlier satiety, because that is precisely what the trial reported — alongside significant weight loss over two six-week periods at 900 mg/day Cangiano 1992. At the 150–300 mg the label directs Office of Dietary Supplements 2023 the effect should be proportionally smaller, which is a prediction worth writing down before starting.

4. Eosinophil count — the prediction with a historical reason behind it. Get a full blood count with differential before starting and at eight weeks. Predict eosinophils stay normal. The reason to look is that in the reported family cluster, one member developed the eosinophilia-myalgia syndrome and two others developed eosinophilia after L-5-HTP exposure, and the eosinophilia in two family members resolved after replacement with pure L-5-HTP Michelson 1994. Eosinophilia preceded and accompanied the syndrome. A rising eosinophil count with new muscle pain is the one combination on this page that means stop today and see somebody.

5. Urinary 5-HIAA, and this one is a warning rather than a benefit. 5-HTP is decarboxylated to serotonin, which monoamine oxidase converts to 5-hydroxyindoleacetic acid. So predict urinary 5-HIAA rises on any effective dose. That matters because urinary 5-HIAA is the screening test for carcinoid tumors: somebody taking 5-HTP who is investigated for flushing or diarrhea can produce an abnormal result that looks like a neuroendocrine tumor. This is a derivation from the pathway rather than a documented case series, and it is labeled as one — but the correct action is the same either way: tell the doctor ordering the test.

6. The prediction that cuts against the product. Predict that mood, measured on a validated scale, does not change at 50–100 mg. The entire acceptable trial base for the mood claim is two trials and 64 patients Shaw 2002, the appetite work used 900 mg Cangiano 1992, and the label's own maximum is a third of that Office of Dietary Supplements 2023. A flat mood score at the card's dose is the expected result, not a personal failure to respond.

What nobody has tested yet

Nobody has tested 5-HTP with and without its own cofactor. The product pairs 5-HTP with pyridoxal 5'-phosphate Office of Dietary Supplements 2023 on an argument that the enzyme distribution suggests is at best neutral. Two arms, one crossover, plasma 5-HTP and plasma serotonin measured: the study is trivial, the ingredient combination is sold by the million, and the experiment has not been published.

Nobody has published a modern slow-release pharmacokinetic curve in a healthy volunteer. The case for reformulating 5-HTP rests on the poor pharmacokinetics of the immediate-release compound Jacobsen 2016; the reference human PK data are from five patients in 1980 Magnussen 1980. A modern study with mass spectrometry, comparing immediate and slow release at the same daily dose, would settle whether the reformulation argument is right.

Nobody has run the trial the systematic review asked for. A review found 108 trials and could use two Shaw 2002. That was published in 2002. In the two decades since, no adequately powered, properly randomized trial of 5-HTP for depression has been completed. For a compound sold in every pharmacy, that is a remarkable absence.

And nobody has resolved the contaminant question with modern methods. Eight of eight commercial samples carried three or more peak X compounds Klarskov 1999; a safety review found no toxic contaminants across several sources Das 2004. Those two statements have coexisted for twenty years without anybody assaying today's market with today's instruments and reporting quantities against a toxicological threshold. The 5-HTP aisle is larger than it has ever been and the last public analysis is a quarter of a century old.

L-5-HTP — its own safety story, not its category's

Serotonin syndrome is the risk that defines this product, and it deserves the clinical detail rather than a warning label. It is caused by excess serotonergic agonism and presents as a triad: mental status change, autonomic hyperactivity and neuromuscular abnormalities — agitation and confusion, fever, tachycardia and sweating, and clonus, hyperreflexia and rigidity that are typically worse in the legs than the arms Boyer 2005. Onset is usually within hours of a dose change or a new drug, and inducible ankle clonus is the single most useful physical sign. It is dose-related rather than idiosyncratic, which is precisely why adding a serotonin precursor to a serotonergic drug is different from adding an unrelated supplement.

The list of drugs that matters, and why 5-HTP is the worst partner in this catalog for them. SSRIs and SNRIs block reuptake; MAO inhibitors block degradation; triptans, tramadol, dextromethorphan, linezolid, lithium and St John's wort all add serotonergic tone Boyer 2005. 5-HTP does something none of those do: it increases the amount of serotonin that exists, by bypassing the only regulated step in its synthesis. A reuptake blocker redistributes a fixed pool; a precursor enlarges it. That is why this is the compound on this site most capable of pushing somebody over the line, and why ‘check with your doctor’ is not the right advice here — do not combine it.

The eosinophilia-myalgia question, presented from both sides. A family cluster was reported in which one member developed an EMS-related disorder and two others developed eosinophilia after L-5-HTP exposure, with the eosinophilia resolving after replacement with pure L-5-HTP Michelson 1994. All eight commercial samples later analyzed contained three or more peak X family contaminants Klarskov 1999. Against that, a safety review after twenty years of worldwide use found no definitive cases of toxicity and no toxic contaminants in several sources examined Das 2004. The reasonable position is neither ‘proven safe’ nor ‘proven dangerous’: it is that a detectable impurity family with a terrible history is present in commercial material, has not been shown to cause harm at the levels found, and has not been re-measured recently.

Do not combine with carbidopa outside medical supervision, and here is why that specific warning exists. Carbidopa is a peripheral decarboxylase inhibitor, so it dramatically increases the fraction of a 5-HTP dose reaching the brain — which is a pharmacological dose escalation without a change in the number of capsules. Anyone on carbidopa-levodopa for Parkinson's disease who adds 5-HTP is running that combination unintentionally, and the resulting central exposure is not the one the label's directions were written for Office of Dietary Supplements 2023.

Two practical ones. Nausea is dose-limiting and predictable from the peripheral decarboxylation described above, and it is the reason the historical trial doses of 900 mg/day Cangiano 1992 are not reachable for most people without a divided schedule and food. And the label directs up to 300 mg a day Office of Dietary Supplements 2023 while the card says 50–100 mg at night — a person following the bottle rather than the page is taking up to six times as much, which is worth knowing before deciding either is right.

And the harm most likely to actually occur. Somebody with depression heavy enough to reach for a serotonin precursor is somebody with a treatable illness. A supplement that takes the edge off has cost them the diagnosis, and the acceptable trial evidence for that use is two trials and 64 people Shaw 2002.

Sources read for this page

• Office of Dietary Supplements, National Institutes of Health. 5-Hydroxytryptophan (Thorne) -- filed Supplement Facts panel: per 2-capsule serving 5-HTP 100 mg and vitamin B6 6.8 mg as pyridoxal 5-phosphate, take 1-2 capsules three times daily; on market. NIH Dietary Supplement Label Database, label recorded 2023
• Magnussen IE, Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacologica et Toxicologica 1980;46(4):257-262 · PMID 6966118
• Jacobsen JPR, et al. Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. Trends in Pharmacological Sciences 2016;37(11):933-944 · PMID 27692695
• Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews 2002;(1):CD003198 · PMID 11869656
• Cangiano C, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. American Journal of Clinical Nutrition 1992;56(5):863-867 · PMID 1384305
• Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine 2005;352(11):1112-1120 · PMID 15784664
• Michelson D, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. Journal of Rheumatology 1994;21(12):2261-2265 · PMID 7699627
• Klarskov K, et al. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Advances in Experimental Medicine and Biology 1999;467:461-468 · PMID 10721089
• Das YT, et al. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 2004;150(1):111-122 · PMID 15068828

How you would know if it worked

L-5-HTP — safety & side effects

Bloodwork to run alongside L-5-HTP

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

L-5-HTP — frequently asked questions

L-5-HTP inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What L-5-HTP is used for

L-5-HTP appears under 2 goals in the goal router.

Related Cognitive & Mood supplements

← Browse the full Supplement Vault

↑ Back to on this page